SMTL ID : 5s9r.1

CRYSTAL STRUCTURE OF THE FIRST BROMODOMAIN OF HUMAN BRD4 IN COMPLEX WITH BMS-986158, 2-{3-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)-5-[(S)-(oxan-4-yl)(phenyl)methyl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.85 Å

Oligo State

monomer

Ligands

1 x YWA: 2-{3-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)-5-[(S)-(oxan-4-yl)(phenyl)methyl]-5H-pyrido[3,2-b]indol-7-yl}propan-2-ol(Non-covalent)

YWA.1: 14 residues within 4Å: Chain A: W.41, P.42, F.43, Q.45, V.47, L.52, L.54, C.96, Y.99, N.100, D.105, I.106, M.109 Ligands: IOD.2 10 PLIP interactions: 10 interactions with chain A Hydrophobic interactions: A:W.41, A:L.52, A:L.52, A:L.54, A:L.54, A:I.106 Hydrogen bonds: A:N.100 Water bridges: A:Q.45, A:Y.57 pi-Stacking: A:W.41

3 x IOD: IODIDE ION(Non-functional Binders)

IOD.2: 3 residues within 4Å: Chain A: D.105, I.106 Ligands: YWA.1 Ligand excluded by PLIP IOD.3: 2 residues within 4Å: Chain A: R.18, Q.19 Ligand excluded by PLIP IOD.4: 2 residues within 4Å: Chain A: N.12, N.14 Ligand excluded by PLIP

2 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)

EDO.5: 6 residues within 4Å: Chain A: I.60, I.61, K.62, T.63, N.95, I.98 6 PLIP interactions: 6 interactions with chain A Hydrogen bonds: A:I.60, A:K.62, A:T.63, A:T.63, A:T.63, A:N.95 EDO.6: 8 residues within 4Å: Chain A: N.4, P.5, P.6, P.7, P.46, V.47, D.48, Y.58 3 PLIP interactions: 3 interactions with chain A Hydrogen bonds: A:P.6, A:V.47, A:Y.58

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Gavai, A.V. et al., Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug Design. J.Med.Chem. (2021)

Release Date

2021-09-29

Peptides

Bromodomain-containing protein 4: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Bromodomain-containing protein 4

Related Entries With Identical Sequence